The PI3K/Akt/PTEN/mTOR pathway: a fruitful target for inducing cell death in rheumatoid arthritis?

PI3K/Akt/mTOR signaling regulates diverse cellular processes. Abnormal PI3K/Akt/mTOR signaling is a characteristic feature of cancer. As such inhibition of PI3K/Akt/mTOR signaling using small molecule inhibitors has been a focus of recently developed anticancer drugs. Rheumatoid arthritis and psoriatic arthritis are autoimmune-mediated inflammatory diseases. PI3K signaling could now be targeted to determine its contribution to rheumatoid and psoriatic arthritis where deregulated proliferation and aberrant survival of activated immune cells, macrophages, monocytes, dendritic cells and synovial fibroblasts significantly overlap with abnormal growth of cancer cells. The results of some recent studies in psoriatic arthritis using PI3K signaling inhibitors suggests that small molecule inhibitor strategies directed at PI3K signaling may be a useful future therapy for immune-mediated arthritis.

[1]  J. Alferink,et al.  The catalytic PI3K isoforms p110γ and p110δ contribute to B cell development and maintenance, transformation, and proliferation , 2010, Journal of leukocyte biology.

[2]  Funda Meric-Bernstam,et al.  Targeting the mTOR signaling network for cancer therapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Y. Takasaki,et al.  Inhibitory effects of ZSTK474, a phosphatidylinositol 3-kinase inhibitor, on adjuvant-induced arthritis in rats , 2012, Inflammation Research.

[4]  A. Arcaro,et al.  The Phosphoinositide 3-Kinase Pathway in Human Cancer: Genetic Alterations and Therapeutic Implications , 2007, Current genomics.

[5]  E. Roman,et al.  New targets for non-small-cell lung cancer therapy , 2007, Expert review of anticancer therapy.

[6]  C. Betz,et al.  Where is mTOR and what is it doing there? , 2013, The Journal of cell biology.

[7]  C. Malemud.  The Discovery of Novel Experimental Therapies for Inflammatory Arthritis , 2010, Mediators of inflammation.

[8]  Yan Luo,et al.  Updates of mTOR inhibitors. , 2010, Anti-cancer agents in medicinal chemistry.

[9]  W. Hörl,et al.  The Multifunctional Role of mTOR in Innate Immunity: Implications for Transplant Immunity , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[10]  A. Shisheva.  PIKfyve and its Lipid products in health and in sickness. , 2012, Current topics in microbiology and immunology.

[11]  R. Abraham,et al.  Targeting mTOR globally in cancer: Thinking beyond rapamycin , 2009, Cell cycle.

[12]  M. Gold,et al.  Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies , 2012, Front. Immun..

[13]  D. Whittington,et al.  Discovery and in Vivo Evaluation of Dual PI3K-beta/delta inhibitors , 2012 .

[14]  M. Belvin,et al.  GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway , 2011, Molecular Cancer Therapeutics.

[15]  S. Guichard,et al.  Delineating the mTOR Kinase Pathway Using a Dual TORC1/2 Inhibitor, AZD8055, in Multiple Myeloma , 2014, Molecular Cancer Therapeutics.

[16]  A. Tee,et al.  mTORC1 drives HIF-1α and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3 , 2014, Oncogene.

[17]  Ji Luo,et al.  The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism , 2006, Nature Reviews Genetics.

[18]  J. Barata,et al.  IL-7R-mediated signaling in T-cell acute lymphoblastic leukemia. , 2013, Advances in biological regulation.

[19]  Gary Box,et al.  The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer . , 2008, Journal of medicinal chemistry.

[20]  K. Okkenhaug,et al.  The PI3K Isoforms p110α and p110δ Are Essential for Pre–B Cell Receptor Signaling and B Cell Development , 2010, Science Signaling.

[21]  R. Parsons,et al.  PTEN function: the long and the short of it. , 2014, Trends in biochemical sciences.

[22]  K. Okkenhaug,et al.  The Therapeutic Potential for PI3K Inhibitors in Autoimmune Rheumatic Diseases , 2012, The open rheumatology journal.

[23]  J. Tamburini,et al.  PI3K and mTOR Signaling Pathways in Cancer: New Data on Targeted Therapies , 2012, Current Oncology Reports.

[24]  E. Peng,et al.  Rapamycin regulates Akt and ERK phosphorylation through mTORC1 and mTORC2 signaling pathways , 2010, Molecular carcinogenesis.

[25]  J. Barata,et al.  PTEN and leukemia stem cells. , 2014, Advances in biological regulation.

[26]  N. Itoh,et al.  The Fibroblast Growth Factor signaling pathway , 2015, Wiley interdisciplinary reviews. Developmental biology.

[27]  J. Baselga.  Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer. , 2011, The oncologist.

[28]  A. Zask,et al.  Recent advances in the development of selective, ATP-competitive inhibitors of mTOR. , 2010, Current opinion in drug discovery & development.

[29]  S. Raychaudhuri,et al.  IL-22 induced cell proliferation is regulated by PI3K/Akt/mTOR signaling cascade. , 2012, Cytokine.

[30]  E. Raymond,et al.  New inhibitors of the mammalian target of rapamycin signaling pathway for cancer , 2010, Expert opinion on investigational drugs.

[31]  K. Stylianou,et al.  The PI3K/Akt/mTOR pathway is activated in murine lupus nephritis and downregulated by rapamycin. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[32]  B. Manning,et al.  A complex interplay between Akt, TSC2 and the two mTOR complexes. , 2009, Biochemical Society transactions.

[33]  Jie Hao,et al.  Targeting Interleukin-22 in Psoriasis , 2013, Inflammation.

[34]  Y. Kitagishi,et al.  PI3K/AKT/PTEN pathway as a target for Crohn's disease therapy (Review). , 2015, International journal of molecular medicine.

[35]  C. Malemud.  Suppression of Pro-Inflammatory Cytokines via Targeting of STAT-Responsive Genes , 2013 .

[36]  S. Koyasu,et al.  Recent advances in understanding the molecular mechanisms of the development and function of Th17 cells , 2013, Genes to cells : devoted to molecular & cellular mechanisms.

[37]  C. Malemud.  Apoptosis Resistance in Rheumatoid Arthritis Synovial Tissue , 2012 .

[38]  K. Anderson,et al.  B-lineage commitment prior to surface expression of B220 and CD19 on hematopoietic progenitor cells. , 2008, Blood.

[39]  J. Dennis,et al.  New organ-specific pharmacological strategies interfering with signaling pathways in inflammatory disorders/autoimmune disorders , 2011 .

[40]  L. Papon,et al.  Distinct Effects of Soluble and Membrane‐Bound Fas Ligand on Fibroblast‐like Synoviocytes From Rheumatoid Arthritis Patients , 2014, Arthritis & rheumatology.

[41]  A. Alghasham,et al.  Therapeutic targets for rheumatoid arthritis: Progress and promises , 2014, Autoimmunity.

[42]  T. Machleidt,et al.  Development of LanthaScreen™ Cellular Assays for Key Components within the PI3K/AKT/mTOR Pathway , 2009, Journal of biomolecular screening.

[43]  S. Sudarsanam,et al.  Functional consequences of mTOR inhibition. , 2010, Current opinion in drug discovery & development.

[44]  L. Weisman,et al.  Phosphatidylinositol 3,5‐bisphosphate: Low abundance, high significance , 2014, BioEssays : news and reviews in molecular, cellular and developmental biology.

[45]  S. Koyasu,et al.  Role of PI3K/Akt and mTOR complexes in Th17 cell differentiation , 2013, Annals of the New York Academy of Sciences.

[46]  N. Hay,et al.  The Akt-mTOR tango and its relevance to cancer. , 2005, Cancer cell.

[47]  T. Weichhart,et al.  The multiple facets of mTOR in immunity. , 2009, Trends in immunology.

[48]  H. Yoshikawa,et al.  IL-6 negatively regulates osteoblast differentiation through the SHP2/MEK2 and SHP2/Akt2 pathways in vitro , 2014, Journal of Bone and Mineral Metabolism.

[49]  C. Rommel,et al.  PI3 kinase δ is a key regulator of synoviocyte function in rheumatoid arthritis. , 2012, The American journal of pathology.

[50]  Charles J Malemud,et al.  Intracellular Signaling Pathways in Rheumatoid Arthritis. , 2013, Journal of clinical & cellular immunology.

[51]  T. Weichhart,et al.  The PI3K/Akt/mTOR pathway in innate immune cells: emerging therapeutic applications , 2008, Annals of the rheumatic diseases.

[52]  M. Holz.  The role of S6K1 in ER-positive breast cancer , 2012, Cell cycle.

[53]  E. Pearlman,et al.  Targeting JAK/STAT Signaling Pathway in Inflammatory Diseases , 2009 .

[54]  S. Raychaudhuri,et al.  mTOR Signaling Cascade in Psoriatic Disease: Double Kinase mTOR Inhibitor a Novel Therapeutic Target , 2014, Indian Journal of Dermatology.

[55]  W. Fu,et al.  Enhancement of PLGF production by 15-(S)-HETE via PI3K-Akt, NF-κB and COX-2 pathways in rheumatoid arthritis synovial fibroblast. , 2013, European journal of pharmacology.

[56]  E. Raymond,et al.  Abstract A168: First results from a phase I trial of AZD8055, a dual mTORC1 and mTORC2 inhibitor. , 2011 .

[57]  G. Canaud,et al.  Inhibition of the mTORC pathway in the antiphospholipid syndrome. , 2014, The New England journal of medicine.

[58]  Y. Kitagishi,et al.  Roles of PI3K/AKT/PTEN Pathway as a Target for Pharmaceutical Therapy , 2013, The open medicinal chemistry journal.

[59]  C. Malemud.  Growth hormone, VEGF and FGF: involvement in rheumatoid arthritis. , 2007, Clinica chimica acta; international journal of clinical chemistry.

[60]  D. Sabatini,et al.  Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. , 2006, Molecular cell.

[61]  P. Savy,et al.  Discovery of novel PI3-kinase δ specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition. , 2012, Journal of medicinal chemistry.

[62]  A. Martelli,et al.  Targeting signaling pathways in T-cell acute lymphoblastic leukemia initiating cells. , 2014, Advances in biological regulation.

[63]  Y. Mao,et al.  The structure of phosphoinositide phosphatases: Insights into substrate specificity and catalysis. , 2015, Biochimica et biophysica acta.

[64]  R. Parsons,et al.  Molecular Pathways: Intercellular PTEN and the Potential of PTEN Restoration Therapy , 2014, Clinical Cancer Research.

[65]  W. Fu,et al.  Enhancement of placenta growth factor expression by oncostatin M in human rheumatoid arthritis synovial fibroblasts , 2013, Journal of cellular physiology.

[66]  E. Choy.  Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. , 2012, Rheumatology.

[67]  Emilio Hirsch,et al.  Blockade of PI3Kγ suppresses joint inflammation and damage in mouse models of rheumatoid arthritis , 2005, Nature Medicine.

[68]  Yongzhou Hu,et al.  Furthering the design and the discovery of small molecule ATP-competitive mTOR inhibitors as an effective cancer treatment , 2013, Expert opinion on drug discovery.

[69]  Jing Chen,et al.  Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor , 2010, Nature Medicine.

[70]  K. Shokat,et al.  New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signaling from a new generation of Tor Kinase Domain Inhibitors (TORKinibs). , 2010, Current topics in microbiology and immunology.

[71]  R. Abraham,et al.  The FRB Domain of mTOR: NMR Solution Structure and Inhibitor Design†,‡ , 2006 .

[72]  D. Fruman,et al.  B Cell Receptor Signaling: Picky About PI3Ks , 2010, Science Signaling.

[73]  C. Baerwald,et al.  Relationship between placenta growth factor 1 and vascularization, dehydroepiandrosterone sulfate to dehydroepiandrosterone conversion, or aromatase expression in patients with rheumatoid arthritis and patients with osteoarthritis. , 2012, Arthritis and rheumatism.

[74]  Lisa L. Smith,et al.  AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. , 2010, Cancer research.

[75]  Nahum Sonenberg,et al.  Dissecting the role of mTOR: lessons from mTOR inhibitors. , 2010, Biochimica et biophysica acta.

[76]  M. Radi,et al.  ATP-competitive inhibitors of mTOR: an update. , 2011, Current medicinal chemistry.

[77]  P. Savy,et al.  Potent and highly selective benzimidazole inhibitors of PI3-kinase delta. , 2012, Journal of medicinal chemistry.

[78]  Howard L McLeod,et al.  PI3K/Akt/mTOR pathway as a target for cancer therapy , 2005, Anti-cancer drugs.

[79]  D. Whittington,et al.  Discovery and in vivo evaluation of dual PI3Kβ/δ inhibitors. , 2012, Journal of medicinal chemistry.

[80]  G. Mariani,et al.  Novel approaches for molecular targeted therapy of breast cancer: interfering with PI3K/AKT/mTOR signaling. , 2013, Current cancer drug targets.

[81]  A. Zask,et al.  Recent advances in the discovery of small-molecule ATP competitive mTOR inhibitors: a patent review , 2011, Expert opinion on therapeutic patents.

[82]  Nicole M. Chapman,et al.  mTOR Links Environmental Signals to T Cell Fate Decisions , 2015, Front. Immunol..

[83]  R. Ulrich,et al.  CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. , 2011, Blood.

[84]  P. Norman.  Selective PI3Kδ inhibitors, a review of the patent literature , 2011, Expert opinion on therapeutic patents.

[85]  M. White,et al.  Regulation of insulin sensitivity by serine/threonine phosphorylation of insulin receptor substrate proteins IRS1 and IRS2 , 2012, Diabetologia.